Billionaire R.J. Kirk's Intrexon has signed a $60 million deal to acquire ActoGeniX, a Belgian biotech at work on oral drugs designed to generate therapeutic proteins and peptides from within the body.
Salix Pharmaceuticals, moving on from an embarrassing inventory scandal, is reportedly headed for a bidding war between two larger companies with diametric approaches to the business of developing drugs.
Earlier this month, rumors started swirling that Valeant was talking with its advisers about a potential bid for North Carolina's Salix Pharmaceuticals. Now, it's reportedly one step closer to making that happen--but it may not be alone.
Shire has some hefty sales forecasts in place for 2020, when CEO Flemming Ornskov has said it'll be bringing in a $10 billion top-line haul. Now, after a monster sales vault in 2014, the company is nearly 60% there--but don't expect a repeat growth surge this year, it says.
When Hospira's proxy was filed last year, CEO F. Michael Ball's $9.9 million in total compensation didn't even rank him among the top 15 highest paid biopharma execs. But with the $15 billion sale of his company to Pfizer, Ball will achieve that goal that CEOs strive for: the payout of the golden parachute. In his case, it is a package that adds up to more than $80 million.
DePuy Synthes will introduce imaging for minimally invasive arthroscopic surgeries with the purchase of Utah-based startup Olive Medical for an undisclosed amount. Orthopedics is one of its stronger medical device businesses and this Johnson & Johnson company is focused on leveraging its scale across it.
Pfizer CEO Ian Read not only isn't done with deals after his Hospira purchase; he's also looking at creative swaps, a la the Novartis-GlaxoSmithKline deals.
The deadline to bid for Dendreon has come and gone, and now that no other qualified bids have come forward, Valeant is walking away victorious.
Whatever GlaxoSmithKline learned about GlycoVaxyn in the two years since they inked a collaboration deal, it must have left the pharma giant feeling confident about the technology. GSK says today that it will scoop up the Swiss biotech, which is working on new vaccines for bacterial infections, for $190 million in cash.
Fending off a hostile bid last year from partners Valeant and activist investor Bill Ackman wasn't just a lot of work, according to Allergan CEO David Pyott. It was a full-time job.